STOCKHOLM JUNE 6th, 2018 – Coala Life has raised an additional 16 million SEK (approx. USD 2 million) in growth capital to further accelerate its commercialization. Investors include 20 North Street, Larry Leksell, international business angels and senior executives in the company.
"We’ve now raised over SEK 110 million [approx. USD 12.5 million] on our mission to develop unique solutions for individual and patient-centered cardiac analysis. It’s about improving clinical accessibility, productivity and sensitivity, and to generate data that can be used to predict heart disease based on our AI-algorithms to help win the battle against the world's leading cause of death", commented Philip Siberg, CEO and co-founder of Coala Life.
The raised capital aims to accelerate commercialization within the consumer market and further drive the digitization of cardiac care.
As of today, the Coala-system has analyzed over 100,000 ECG’s with approximately 100 healthcare providers and 250 physicians connected to the platform. Many previously unknown cases of heart disease have been detected and treated, and the solutions have shown to improve healthcare productivity and alleviate worries with very strong clinical sensitivity and specificity.
Coala Life was founded and supported by a number of leading entrepreneurs, industry leaders and investors in the Life Science industry including Larry Leksell (chairman and founder of Elekta AB), Sören Olofsson (former CEO of some of Sweden’s largest hospitals and County Council CEO) and Liselott Kilaas (former President and CEO of Aleris, the largest health care provider in Scandinavia).
For more info:
Philip Siberg, CEO and co-founder, +46 70 7906734, email@example.com
Titti Lundgren, Chief Marketing Officer, +46 708 3533 28, firstname.lastname@example.org